Rabeprazole
- Generic Name
- Rabeprazole
- Brand Names
- Aciphex, Pariet
- Drug Type
- Small Molecule
- Chemical Formula
- C18H21N3O3S
- CAS Number
- 117976-89-3
- Unique Ingredient Identifier
- 32828355LL
- Background
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
- Indication
For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
- Associated Conditions
- Duodenal Ulcer, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Heartburn, Helicobacter Pylori Infection, Non-erosive Reflux Esophagitis Disease (NERD), Vomiting, Zollinger-Ellison Syndrome, Develop NSAID-induced gastric ulcers, Erosive reflux esophagitis
Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Rabeprazole Sodium Delayed Release Tablets Under Fed Conditions
- Conditions
- Healthy
- First Posted Date
- 2013-11-21
- Last Posted Date
- 2013-11-21
- Lead Sponsor
- Torrent Pharmaceuticals Limited
- Registration Number
- NCT01990586
- Locations
- 🇮🇳
AXIS Clinicals Limited, Miyapur, Hyderabad, India
A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors
- Conditions
- Cancer
- Interventions
- First Posted Date
- 2013-10-01
- Last Posted Date
- 2017-11-14
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 23
- Registration Number
- NCT01954043
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Concomitant Therapy of H. Pylori
- Conditions
- Gastritis, Gastric Ulcer, and Duodenal Ulcer
- Interventions
- First Posted Date
- 2013-08-14
- Last Posted Date
- 2014-02-11
- Lead Sponsor
- The Catholic University of Korea
- Target Recruit Count
- 540
- Registration Number
- NCT01922765
- Locations
- 🇰🇷
Yeouido St. Mary's Hospital, Seoul, Korea, Republic of
A Drug-Drug Interaction Study of the Effect of Rabeprazole, Itraconazole or Fluconazole on the Pharmacokinetics of Vismodegib
- Conditions
- Healthy Volunteer
- Interventions
- First Posted Date
- 2013-01-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 92
- Registration Number
- NCT01772290
Effects of YF476 and Rabeprazole on Gastric Function
- Conditions
- Hypergastrinaemia
- First Posted Date
- 2012-10-03
- Last Posted Date
- 2012-10-03
- Lead Sponsor
- Trio Medicines Ltd.
- Target Recruit Count
- 32
- Registration Number
- NCT01699113
- Locations
- 🇬🇧
Hammersmith Medicines Research, London, United Kingdom
New Dual Therapy for Primary Treatment of Helicobacter Pylori Infection：a Pilot Study
- Conditions
- Functional Dyspepsia
- Interventions
- First Posted Date
- 2012-01-20
- Last Posted Date
- 2012-01-20
- Lead Sponsor
- Shanghai Jiao Tong University School of Medicine
- Target Recruit Count
- 40
- Registration Number
- NCT01513785
- Locations
- 🇨🇳
GI Division, Shanghai Jiao-Tong University School of Medicine Renji Hospital, Shanghai, Shanghai, China
Narrow-band Imaging, Autofluorescence Imaging and Gastroesophageal Reflux Disease
- Conditions
- Gastroesophageal Reflux Disease
- Interventions
- Other: symptom questionaireProcedure: pH monitoringProcedure: Tri-modal imaging endoscopy
- First Posted Date
- 2012-01-06
- Last Posted Date
- 2015-09-02
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 95
- Registration Number
- NCT01504971
- Locations
- 🇨🇳
Outpatient Department Building, Beijing, Beijing, China
ASP (PPI_H2RA) Study-H2RA Versus PPI for the Prevention of Recurrent UGIB in High-risk Users of Low-dose ASA
- Conditions
- Upper Gastrointestinal Bleeding
- Interventions
- First Posted Date
- 2011-08-03
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- Chinese University of Hong Kong
- Target Recruit Count
- 264
- Registration Number
- NCT01408186
- Locations
- 🇯🇵
Department of Gastroenterology, Osaka City General Hospital, Osaka, Japan (Satellite hospital of Osaka City University), Osaka, Japan
🇯🇵Department of Internal Medicine and Gastroenterology, Saga Medical School, Saga, Japan, Saga, Japan
🇯🇵Second Department of Internal Medicine, Osaka Medical College, Takatsuki, Osaka, Japan, Osaka, Japan
Long-term Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)
- Conditions
- Gastric Ulcers Duodenal Ulcers Caused by Low-dose Aspirin
- Interventions
- First Posted Date
- 2011-07-20
- Last Posted Date
- 2015-12-21
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 405
- Registration Number
- NCT01398410
Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)
- Conditions
- Gastric or Duodenal Ulcers Caused by Low-dose Aspirin
- Interventions
- First Posted Date
- 2011-07-19
- Last Posted Date
- 2014-11-26
- Lead Sponsor
- Eisai Co., Ltd.
- Target Recruit Count
- 472
- Registration Number
- NCT01397448
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.